Veristat: Advancing Revolutionary Therapies (ART): Orphan Drug Designations and Orphan Subsets

Citeline Podcasts - A podcast by Citeline

Try Bookbeat 60! days for free, click here

Try Bookbeat 60! days for free, click here

Enjoy a whole world of audiobooks and e-books, everything from new releases to the classics

 Sponsored

Categories:

Business

Find out more now about US FDA’s Orphan Drug Designation (ODD) program, which qualifies sponsors for incentives including tax credits, exemption from user fees, and more. Learn more about which orphan subsets could qualify for ODD, in your free podcast episode

Visit the podcast's native language site